Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Janssen Biotech, Inc.
483
•Janssen Biotech, Inc.•July 29, 2025

Janssen Biotech, Inc. – FDA 483, Jul 29, 2025

Record Details

An FDA 483 document issued on July 29, 2025, to an unnamed firm by the Philadelphia District Office, details significant observations regarding its operational and quality control practices. The inspection highlights two primary areas of non-compliance under the Federal Food, Drug, and Cosmetic Act.

Firstly, deficiencies were noted in the firm s laboratory controls concerning bioburden testing. The method validation and verification procedures did not align with current compendial requirements, failing to incorporate updates or adequately evaluate previous validations. Critically, observed bactericidal effects in several test articles during bioburden method validation were not properly remediated, meaning the test method was not modified to overcome these issues, and the validation did not account for potential batch-to-batch variations, thereby compromising the assurance of drug product identity, strength, quality, and purity.

Secondly, the firm failed to conduct thorough reviews of Out-of-Specification (OOS) test results. Specifically, an investigation into a failed osmolarity test for a raw material lacked scientific soundness. The root cause identified to invalidate the initial OOS result was not justified, and no additional studies were performed to rule out laboratory errors. An acceptable retest result from a different media vial was used to invalidate the initial OOS without supporting evidence for the invalidity of the first result or for potential product variability.

These observations require the firm to propose and implement corrective actions to address the identified deficiencies and ensure compliance with regulatory standards.

Company
Janssen Biotech, Inc.
Inspection date
July 29, 2025
Product type
drugs
Office
Philadelphia District Office
People
  • Junho Pak (Investigator)
  • Syeda N. Mahazabin (Drug Investigator)
  • Ruben C. Quintana
View Company Profile

ID · 91999c27-fff3-4a2e-af28-81a6a8053369

Other documents for Janssen Biotech, Inc.
  • EIR - 2018-11-30November 30, 2018
  • EIR - 2018-03-05March 5, 2018
  • 483 - 2018-03-05March 5, 2018
  • 483 - 2017-05-18May 18, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Janssen Biotech, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.